147 results about "Neoplastic disease" patented technology

The present application discloses substituted polycyclic heterocycles compound of Formula (I), pharmaceutically acceptable salt and / or solvate and pharmaceutical compositions thereof useful in the treatment of proliferative disease or condition characterized by a dysregulation of the RAS-ERK pathway such as neoplasm disease or disorder, inflammatory disease or immune system disorder.

The invention discloses a brain tumor disease treatment effect evaluation method, and belongs to the technical field of radiotherapy plan evaluation, and the method specifically comprises the steps: obtaining the brain multi-modal image data of a patient, and extracting a three-dimensional tumor region and a corresponding perfusion parameter; constructing a biological target region hierarchical structure containing a tumor overall region and an anoxic subregion; a relative hypoxia degree parameter is obtained by calculating the cerebral blood flow ratio of the hypoxia subregion to other regions of the tumor; historical treatment case data are deconstructed, and a dose-curative effect associated parameter set is established; training and outputting a dose adjustment strategy model for the hypoxia subregion; and generating a final radiotherapy dose planning scheme according to a dose adjustment value output by the model in combination with a clinical guide basic dose. Through a data-driven dose decision-making mechanism, the limitation of traditional uniform dose irradiation is overcome, so that an objective and reliable evaluation basis is provided for clinical selection and optimization of personalized treatment schemes.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, e.g., a camptothecin cytotoxic molecule which is cell-permeable; as a second payload a topoisomerase I inhibitor which is not cell-permeable, e..g., a camptothecin cytotoxic molecule which is not cell-permeable; and as a as a third payload a toxin or a cytotoxin, e.g., an auristatin such asMMAE (Monomethyl auristatin E). Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The use of a combination of a pyrido[2,3-d]pyrimidin-2(1H)-one derivative and an anti-PD-1 or anti-PD-L1 antibody and / or a chemotherapeutic drug in the preparation of a drug for preventing or treating a tumor disease.

The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The invention belongs to the field of natural medicines and medicinal chemistry, and discloses a thiotriptolide derivative and a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention discloses a thiotriptolide derivative shown as a general formula I and a general formula II. The derivatives are prepared in an artificial synthesis mode, pharmaceutical compositions containing the derivatives, and uses of the derivatives in preparation of drugs for treating tumor diseases.

In one aspect, the disclosure relates to immunogenic compositions comprising a semisynthetic saponin adjuvant (VSA) including, but not limited to, VSA-1 and VSA-2, derived from a Momordica saponin and at least one antigen. In a further aspect, the immunogenic compositions can include other known adjuvants, emulsifiers, and / or surface-active agents and can be formulated as liposomes, micelles, emulsions, and the like. Also disclosed are methods of eliciting effective immune responses to viral, bacterial, protozoal, and neoplastic diseases using the disclosed immunogenic compositions.

Various embodiments of the invention provide binding agents for glypican-3 (GPC3), including antibodies or antigen-binding fragments thereof that bind to GPC3 and antigen recognizing receptors (e.g., CARs) that target GPC3 including cells that express GPC3. Embodiments of the i n vention also provide cells comprising such binding agents such as CAR T-cells, therapeutic compositions comprising such cells and methods of using one or more of the binding agents, cells or therapeutic compositions for the treatment of diseases or disorders associated with GPC3 expression such as various neoplastic diseases or disorders (e.g., hepatocellular carcinoma). Various embodiments of the invention also provide methods and systems for treati ng hepatocellular carcinoma (HCC) utilizing a combi nation of radiofrequency (RF) ablation and GPC3-targeted cell therapy. In certain embodiments, immune modulators, such as checkpoint inhibitors, may be co-administered to potentiate immune responses. Additionally, compositions and kits comprising RF ablation devices and GPC3-targeted cell therapy formulations are provided.

The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10, and wherein R1, X, R2 and R10 are as defined in the claims, as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.

The present invention relates to a device for intravascular drug delivery, preferably an implant for intravascular drug delivery. The invention also relates to a device for a method for preventing or treating neurological diseases, neoplastic diseases, cardiac diseases, vascular diseases, immune diseases, carcinoids, infectious diseases and / or edema.

Bacterial strains are provided having at least one of a reduced size, a sialic acid coat, inducibly altered surface antigens, and expression of PD-L1 or CTLA-4 antagonists and / or tryptophanase. The bacteria may have improved serum half-life, increased penetration into tumors, increased tumor targeting and increased antitumor activity. The bacteria are useful for delivery of therapeutic agents that treat neoplastic diseases including solid tumors and lymphomas.

The present invention provides a computer implemented method for the prediction of clinical outcomes in patients with cancer or pre-neoplastic conditions through the integration of genomic evolutionary, genomic and clinical. More specifically, the invention provides systems and algorithms that generate prognostic and predictive models based on the combined analysis of molecular features, inferred evolutionary routes, and clinical parameters, enabling patient risk stratification and individualized outcome estimation.

The invention relates to application of an active component in preparation of a medicine for treating tumor diseases. Specifically, it is found for the first time that small-molecule isovaleric acid and the prodrug thereof can inhibit DNA homologous recombination so as to efficiently inhibit tumor growth, and isovaleric acid and the prodrug thereof can be combined with chemotherapeutic drugs for radiotherapy, DNA damage induction or DNA synthesis inhibition to generate a synergistic tumor treatment effect.

Provided herein are methods of determining a treatment for a subject having a neoplastic disease, said method comprising assaying a sample obtained from the subject for (a) SAC activity, (b) ploidy, (c) WGD, (d) APC / C activity, or (e) a combination thereof. In exemplary embodiments, the treatment determined for the subject comprises, consists essentially of, or consists of a KIF18A inhibitor, when the sample is positive for (a) increased SAC activity, (b) high ploidy, (c) WGD, (d) low APC / C activity, (d) or a combination thereof.

The invention discloses a fusion protein and application thereof. The fusion protein comprises an anti-VEGFR2 (vascular endothelial growth factor receptor 2) antibody and an IL-10 monomer; wherein the IL-10 monomer is connected with the anti-VEGFR2 (vascular endothelial growth factor receptor 2) antibody. The fusion protein provided by the invention has the advantages of strong targeting property, small side effect, good drug effect and the like. The fusion protein can be used for preparing pharmaceutical compositions or drugs, and can be used for treating or preventing tumor diseases.

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, an ester, a prodrug or a pharmaceutically acceptable salt thereof, and the compound has a good p53-Y220C mutant activation effect and can be used for treating tumor diseases containing p53-Y220C mutant protein. And preparation of medicaments for such conditions or diseases.

The present invention relates to a camptothecin derivative represented by Formula I, a pharmaceutical composition, and a method for preparing and using the same. The camptothecin derivative has good tumor-inhibiting activity and can be used to treat or prevent tumors and to prepare medicines for treating or preventing neoplastic diseases. [Formula 1] JPEG2025541854000098.jpg49169

Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Pharmaceutical compositions, and methods of production and use for the treatment of neoplastic disease in a mammalian animal. When administered to an animal, the pharmaceutical compositions are useful for the treatment of neoplastic diseases such as various cancers, particularly those affecting mammalian animals such as companion animals.

Pharmaceutical compositions, and methods of production and use for the treatment of neoplastic disease in a mammalian animal. When administered to an animal, the pharmaceutical compositions are useful for the treatment of neoplastic diseases such as various cancers, particularly those affecting mammalian animals such as companion animals.

Disclosed is an application of a compound based on a 3-phenyl-1,2,4-oxadiazole-5-carboxamide scaffold in the preparation of a drug for treating tumor diseases. The compound of the 3-phenyl-1,2,4-oxadiazole-5-carboxamide scaffold regulates the level of Cofilin1 palmitoylation modification by inhibiting the activity of PPT2, and finally achieves an anticancer effect.

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.

Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, preferably a camptothecin cytotoxic molecule which is cell-permeable; and as a second payload a topoisomerase I inhibitor which is not cell-permeable, preferably a camptothecin cytotoxic molecule which is not cell-permeable. Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described is an ADC for use in a method of treating a patient suffering from, being at risk of developing, and / or being diagnosed for a neoplastic disease.

The invention discloses an MIF small-molecule inhibitor as well as a screening method and application thereof, and belongs to the technical field of medicinal chemistry. The inhibitor is composed of seven compounds with specific structures and pharmaceutically acceptable salts thereof, and the compounds and the pharmaceutically acceptable salts can effectively inhibit the tautomerase activity of MIF. The lead compounds are efficiently found from a large number of compounds through a computer-aided virtual screening method. In-vitro and in-vivo experiments show that the compound F3277-0933, especially the compound F3277-0933, shows remarkable MIF inhibitory activity and anti-tumor effect in enzyme level, cellular level and animal models, and the effect of the compound F3277-0933 is superior to that of an existing inhibitor ISO-1. The MIF small-molecule inhibitor disclosed by the invention provides a new candidate compound for developing medicines for treating MIF-related diseases such as colorectal cancer.

The present application relates to the use of antibody-drug conjugates, wherein the antibody is a bispecific antibody or an antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds to c-MET and a second antigen-binding domain that specifically binds to EGFR, in treating diseases associated with abnormal cell activity in subjects, such as tumor diseases, wherein the relevant genes of the subjects suffering from the tumor diseases are mutant or wild-type, and they have undergone or have not undergone first-line or second-line treatment.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

Use and methods of drug conjugates for treating neoplastic diseases are provided. Specifically, the invention provides application and a method of a bioactive substance conjugate shown as a formula (I) in treatment of HR < + > / Her2-breast cancer. Formula (I): {D-[L1-(L2) m1-(L3) m2-(L4) m3-E]} gamma-A.

The invention relates to application and a method for treating tumor diseases by using a drug conjugate. Specifically, provided are uses and methods of biologically active conjugate of formula (I) in the treatment of neoplastic diseases, particularly preferably treating locally advanced or metastatic solid tumors, particularly non-small cell lung cancer, which are refractory to treat and cannot be resected by surgery, according to existing standards.